- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
South San Francisco Today
By the People, for the People
Rhenman & Partners Asset Management AB Boosts Stake in Cytokinetics
The institutional investor increased its position in the biopharmaceutical company by nearly 145% in the third quarter.
Published on Mar. 8, 2026
Got story updates? Submit your updates here. ›
Rhenman & Partners Asset Management AB raised its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK) by 144.8% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor now owns 255,250 shares of the biopharmaceutical company's stock, making it the 26th largest holding in its portfolio.
Why it matters
Cytokinetics is a late-stage biopharmaceutical company focused on developing novel treatments for diseases characterized by impaired muscle performance. The significant increase in Rhenman & Partners' stake suggests the firm sees strong potential in Cytokinetics' pipeline and future growth prospects.
The details
Rhenman & Partners Asset Management AB added 151,000 shares of Cytokinetics to its portfolio in the third quarter, bringing its total position to 255,250 shares. This represents approximately 0.21% of the biopharmaceutical company's outstanding shares. The firm cited Cytokinetics' promising drug candidates and market opportunities as reasons for the increased investment.
- Rhenman & Partners Asset Management AB filed its most recent 13F report with the SEC in the third quarter of 2026.
The players
Rhenman & Partners Asset Management AB
A Swedish institutional investment firm that manages a portfolio focused on the healthcare and pharmaceutical sectors.
Cytokinetics, Incorporated
A late-stage biopharmaceutical company developing novel treatments for diseases characterized by impaired muscle performance.
The takeaway
Rhenman & Partners' significant increase in its Cytokinetics stake suggests the firm sees strong potential in the biopharmaceutical company's pipeline and future growth prospects, underscoring the market's optimism around Cytokinetics' innovative muscle-focused drug candidates.
